In Brief: Glaxo Wellcome Zyloprim
Glaxo Wellcome Zyloprim: Allopurinol sodium eq 500 mg base/vial injection approved May 17 for management of patients with leukemia, lymphoma and solid tumors receiving cancer therapy that causes uric acid level elevations and who cannot tolerate oral Zyloprim therapy. The injectable xanthine oxidase inhibitor was recommended for approval by an FDA advisory committee in March 1993 and became "approvable" in October...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth